<p>新的 &#34;无障碍套餐&#34; 帮助雇主通过与 9amHealth 的心脏代谢护理平台集成的透明、以结果为导向的模型，提供 FDA 批准的肥胖管理药物和护理的访问。</p>
<p>, /PRNewswire/ -- 9amHealth，虚拟心脏代谢护理的领导者，今天宣布了一项新产品，旨在为雇主提供更可持续的肥胖管理药物和护理的访问。 &#34;无障碍套餐&#34; 提供来自礼来公司（Eli Lilly and Company）和诺和诺德（Novo Nordisk）的 FDA 批准的肥胖药物，以及 9amHealth 的全面心脏代谢护理计划，为雇主支持团队健康创造了一个透明、成本高效的途径。</p>
<p>目前，超过一半的大型雇主覆盖 GLP-1 药物。通过推出这一新产品，9amHealth 将提供一个清晰且可预测的模型，为药物和整体护理成本带来透明度，包括为拥有有效、符合标签处方的患者提供诺和诺德和礼来产品的访问。雇主可以在临床监督、集成数据和以安全、结果和可负担性为重点的护理模型的支持下，负责任地扩展覆盖范围。</p>
<p>&#34;雇主希望为他们的员工做正确的事情，但不断上升的医疗成本和复杂性使得肥胖护理覆盖变得难以管理，&#34; 9amHealth 的联合创始人兼首席运营官 Paul Geevarghese 说。&#34;我们构建这些解决方案是为了给雇主提供透明度和可预测性，同时确保员工获得安全的、 FDA 批准的肥胖管理药物和临床指导的护理。这一合作努力旨在使访问变得可持续，而不仅仅是可能。&#34;</p>
<p><em>无障碍套餐</em> 的服务包括：</p>
<ul>
<li>个性化护理计划</li>
<li>由持证提供者进行的医疗评估</li>
<li>家庭实验室检测和连接设备</li>
<li>如果医学上适当，提供处方药物的访问</li>
<li>专家主导的营养和健身指导</li>
<li>来自医生、内分泌专家、肥胖专家、营养师和药剂师的持续支持</li>
</ul>
<p>&#34;雇主们继续告诉我们，他们希望更好地支持员工的健康，但在提供肥胖管理药物的覆盖方面面临真正的挑战，例如 Zepbound®，&#34; 礼来公司美国雇主高级副总裁 Kevin Hern 说。&#34;我们很高兴与那些分享我们消除摩擦、简化雇主扩展肥胖管理药物访问选项承诺的组织合作。&#34;</p>
<p>&#34;在诺和诺德，我们希望让人们更容易开始和坚持他们所需的药物，改善对真实的、 FDA 批准的 Wegovy® 的访问对许多寻求减肥、心血管风险或 MASH 治疗的人来说可以发挥重要作用，&#34; 诺和诺德市场与患者解决方案高级副总裁 Ed Cinca 说。&#34;我们欢迎通过无摩擦的方式让患者更容易优先考虑他们的健康的机会。&#34;</p>
<p><strong>关于 9amHealth</strong></p>
<p>9amHealth 提供完整的心脏代谢护理——一种首创的整体方法，用于预防和治疗肥胖、糖尿病、高胆固醇和高血压。他们与雇主、健康计划和药品福利管理公司合作，为那些生活在慢性病中的人提供有效的健康福利。会员获得个性化的护理计划，享有无限制的专家访问、专家主导的营养和健身支持、处方和实验室检测。</p>
<p>来源 9amHealth</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIxJk5ld3NJdGVtSWQ9TEEzMDUwMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjEwODAwUFJfTkVXU19VU1BSX19fX19MQTMwNTAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIxJk5ld3NJdGVtSWQ9TEEzMDUwMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjEwODAwUFJfTkVXU19VU1BSX19fX19MQTMwNTAy"/></p>

诺和诺德公司

礼来

<p>9amHealth 宣布推出 “No-Barriers Bundle”，这是一个新的产品，旨在通过雇主健康福利扩大对肥胖管理药物的获取。该套餐包括来自礼来和诺和诺德公司的 FDA 批准药物，并与 9amHealth 的心脏代谢护理平台整合。其目标是为雇主提供一个透明且具有成本效益的途径，以支持员工健康，解决肥胖护理覆盖方面的挑战</p>

<p><em>The new &#34;No-Barriers Bundle&#34; helps employers enable access to FDA-approved obesity management medications and care through a transparent, outcomes-driven model integrated with 9amHealth's cardiometabolic care platform.</em></p>
<div class="lb-trans"><p>新的 &#34;无障碍套餐&#34; 帮助雇主通过与 9amHealth 的心脏代谢护理平台集成的透明、以结果为导向的模型，提供 FDA 批准的肥胖管理药物和护理的访问。</p>
</div><p>, /PRNewswire/ -- 9amHealth, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The &#34;No-Barriers Bundle&#34; offers access to FDA-approved obesity medicines from Eli Lilly and Company (Lilly) and Novo Nordisk, along with 9amHealth's comprehensive cardiometabolic care program, creating a transparent, cost-efficient pathway for employers to support their teams' health.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 9amHealth，虚拟心脏代谢护理的领导者，今天宣布了一项新产品，旨在为雇主提供更可持续的肥胖管理药物和护理的访问。 &#34;无障碍套餐&#34; 提供来自礼来公司（Eli Lilly and Company）和诺和诺德（Novo Nordisk）的 FDA 批准的肥胖药物，以及 9amHealth 的全面心脏代谢护理计划，为雇主支持团队健康创造了一个透明、成本高效的途径。</p>
</div><p>Currently, just over half of large employers cover GLP-1 medications. Through the launch of this new offering, 9amHealth will provide a clear and predictable model that brings transparency to medication and total care costs, including access to both Novo Nordisk and Lilly products for patients with a valid, on-label prescription. Employers gain the confidence to extend coverage responsibly—supported by clinical oversight, integrated data, and a care model focused on safety, outcomes, and affordability.</p>
<div class="lb-trans"><p>目前，超过一半的大型雇主覆盖 GLP-1 药物。通过推出这一新产品，9amHealth 将提供一个清晰且可预测的模型，为药物和整体护理成本带来透明度，包括为拥有有效、符合标签处方的患者提供诺和诺德和礼来产品的访问。雇主可以在临床监督、集成数据和以安全、结果和可负担性为重点的护理模型的支持下，负责任地扩展覆盖范围。</p>
</div><p>&#34;Employers want to do the right thing for their people—but rising healthcare costs and complexity have made obesity care coverage difficult to manage,&#34; said Paul Geevarghese, Co-Founder and Chief Operating Officer at 9amHealth. &#34;We built these solutions to give employers transparency and predictability while ensuring employees receive safe, FDA-approved obesity management medications and clinically guided care. This collaborative effort is about making access sustainable, not just possible.&#34;</p>
<div class="lb-trans"><p>&#34;雇主希望为他们的员工做正确的事情，但不断上升的医疗成本和复杂性使得肥胖护理覆盖变得难以管理，&#34; 9amHealth 的联合创始人兼首席运营官 Paul Geevarghese 说。&#34;我们构建这些解决方案是为了给雇主提供透明度和可预测性，同时确保员工获得安全的、 FDA 批准的肥胖管理药物和临床指导的护理。这一合作努力旨在使访问变得可持续，而不仅仅是可能。&#34;</p>
</div><p>Services of the <em>No-Barriers Bundle</em> include:</p>
<div class="lb-trans"><p><em>无障碍套餐</em> 的服务包括：</p>
</div><ul>
<li>Personalized care plans</li>
<li>Medical evaluation by licensed providers</li>
<li>At-home lab testing and connected devices</li>
<li>Access to prescription medications, if medically appropriate</li>
<li>Expert-led nutrition and fitness guidance</li>
<li>Ongoing support from physicians, endocrinologists, obesity specialists, dietitians, and pharmacists</li>
</ul>
<div class="lb-trans"><ul>
<li>个性化护理计划</li>
<li>由持证提供者进行的医疗评估</li>
<li>家庭实验室检测和连接设备</li>
<li>如果医学上适当，提供处方药物的访问</li>
<li>专家主导的营养和健身指导</li>
<li>来自医生、内分泌专家、肥胖专家、营养师和药剂师的持续支持</li>
</ul>
</div><p>&#34;Employers continue to tell us they want to better support their employees' health but face real challenges in providing coverage for obesity management medicines, like Zepbound®,&#34; said Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA. &#34;We're excited to collaborate with organizations that share our commitment to removing friction and streamlining options for employers to expand access to obesity management medicines for people who need them.&#34;</p>
<div class="lb-trans"><p>&#34;雇主们继续告诉我们，他们希望更好地支持员工的健康，但在提供肥胖管理药物的覆盖方面面临真正的挑战，例如 Zepbound®，&#34; 礼来公司美国雇主高级副总裁 Kevin Hern 说。&#34;我们很高兴与那些分享我们消除摩擦、简化雇主扩展肥胖管理药物访问选项承诺的组织合作。&#34;</p>
</div><p>&#34;At Novo Nordisk, we want to make it easier for people to start and stay on the medications that they need, and improving access to authentic, FDA-approved Wegovy® can play an essential role for many seeking treatment for weight loss, CV risk, or MASH,&#34; said Ed Cinca, Senior Vice President, Marketing and Patient Solutions at Novo Nordisk. &#34;We embrace opportunities to make it easier for patients to prioritize their health through frictionless access to these medicines.&#34;</p>
<div class="lb-trans"><p>&#34;在诺和诺德，我们希望让人们更容易开始和坚持他们所需的药物，改善对真实的、 FDA 批准的 Wegovy® 的访问对许多寻求减肥、心血管风险或 MASH 治疗的人来说可以发挥重要作用，&#34; 诺和诺德市场与患者解决方案高级副总裁 Ed Cinca 说。&#34;我们欢迎通过无摩擦的方式让患者更容易优先考虑他们的健康的机会。&#34;</p>
</div><p><strong>About 9amHealth</strong></p>
<div class="lb-trans"><p><strong>关于 9amHealth</strong></p>
</div><p>9amHealth offers complete cardiometabolic care—a first-of-its-kind, whole-body approach to preventing and treating obesity, diabetes, high cholesterol, and hypertension. They partner with employers, health plans, and PBMs to provide effective health benefits for those living with chronic conditions. Members get personalized care plans with unlimited access to specialists, expert-led nutrition and fitness support, prescriptions, and lab testing.</p>
<div class="lb-trans"><p>9amHealth 提供完整的心脏代谢护理——一种首创的整体方法，用于预防和治疗肥胖、糖尿病、高胆固醇和高血压。他们与雇主、健康计划和药品福利管理公司合作，为那些生活在慢性病中的人提供有效的健康福利。会员获得个性化的护理计划，享有无限制的专家访问、专家主导的营养和健身支持、处方和实验室检测。</p>
</div><p>SOURCE 9amHealth</p>
<div class="lb-trans"><p>来源 9amHealth</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIxJk5ld3NJdGVtSWQ9TEEzMDUwMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjEwODAwUFJfTkVXU19VU1BSX19fX19MQTMwNTAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA30502&amp;Transmission_Id=202511210800PR_NEWS_USPR_____LA30502&amp;DateId=20251121"/></p>

9amHealth 将通过新的雇主健康福利计划扩大肥胖管理治疗的可及性